Multiple Myeloma | Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma

Featuring an interview with Dr Joshua Richter, including the following topics:

• Management of cytokine release syndrome after bispecific antibody therapy; importance of clinical trials in the multiple myeloma (MM) treatment paradigm (0:00)
• Similarities and differences between and efficacy and tolerability of BCMA- and non-BCMA-directed bispecific antibodies in the treatment of MM (7:18)
• Case: A woman in her mid 60s with penta-refractory MM who achieves complete remission with linvoseltamab on a clinical trial (12:53)
• Case: A woman in her early 60s with multiregimen-refractory MM who experiences pain and tumor flare during step-up dosing of teclistamab (22:40)
• Case: A man in his late 60s with relapsed/refractory MM who experiences disease relapse 18 months after chimeric antigen receptor T-cell therapy begins treatment with talquetamab (28:34)
• Racial and ethnic disparities in the treatment of MM (32:09)

CME information and select publications